株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Etubics Corporation:製品パイプライン分析

Etubics Corporation - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251664
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Etubics Corporation:製品パイプライン分析 Etubics Corporation - Product Pipeline Review - 2016
出版日: 2016年02月24日 ページ情報: 英文 35 Pages
概要

Etubics Corporation は、免疫療法と抗癌ワクチンの発見・開発・商品化に力を入れているバイオ製薬会社です。同社はまた、インフルエンザやマラリア、HIVなどといった感染症の予防ワクチンも提供しています。

当レポートでは、Etubics Corporation における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Etubics Corporation の基本情報

  • Etubics Corporationの概要
  • 主要情報
  • 企業情報

Etubics Corporation:R&Dの概要

  • 主な治療範囲

Etubics Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Etubics Corporation:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Etubics Corporation:薬剤プロファイル

  • ETBX-011
  • ETBX-021
  • Recombinant Vector Vaccine for HIV
  • Recombinant Vector Vaccine for Influenza
  • Recombinant Vector Vaccine for Malaria
  • Vaccine for HPV-Head and Neck Cancer

Etubics Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別

Etubics Corporation:最近のパイプライン動向

Etubics Corporation:休止中のプロジェクト

Etubics Corporation:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07956CDB

Summary

Global Markets Direct's, 'Etubics Corporation - Product Pipeline Review - 2016', provides an overview of the Etubics Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Etubics Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Etubics Corporation
  • The report provides overview of Etubics Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Etubics Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Etubics Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Etubics Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Etubics Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Etubics Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Etubics Corporation Snapshot
    • Etubics Corporation Overview
    • Key Information
    • Key Facts
  • Etubics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Etubics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Etubics Corporation - Pipeline Products Glance
    • Etubics Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Etubics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Etubics Corporation - Drug Profiles
    • ETBX-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ebola vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETBX-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Auditory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIV vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H1N1] (mutivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for HPV Associated Head and Neck Squamous Cell Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chikungunya vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lassa fever vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Etubics Corporation - Pipeline Analysis
    • Etubics Corporation - Pipeline Products by Target
    • Etubics Corporation - Pipeline Products by Route of Administration
    • Etubics Corporation - Pipeline Products by Molecule Type
    • Etubics Corporation - Pipeline Products by Mechanism of Action
  • Etubics Corporation - Recent Pipeline Updates
  • Etubics Corporation - Dormant Projects
  • Etubics Corporation - Locations and Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Etubics Corporation, Key Information
  • Etubics Corporation, Key Facts
  • Etubics Corporation - Pipeline by Indication, 2016
  • Etubics Corporation - Pipeline by Stage of Development, 2016
  • Etubics Corporation - Monotherapy Products in Pipeline, 2016
  • Etubics Corporation - Phase I, 2016
  • Etubics Corporation - Preclinical, 2016
  • Etubics Corporation - Discovery, 2016
  • Etubics Corporation - Pipeline by Target, 2016
  • Etubics Corporation - Pipeline by Route of Administration, 2016
  • Etubics Corporation - Pipeline by Molecule Type, 2016
  • Etubics Corporation - Pipeline Products by Mechanism of Action, 2016
  • Etubics Corporation - Recent Pipeline Updates, 2016
  • Etubics Corporation - Dormant Developmental Projects,2016

List of Figures

  • Etubics Corporation - Pipeline by Top 10 Indication, 2016
  • Etubics Corporation - Pipeline by Stage of Development, 2016
  • Etubics Corporation - Monotherapy Products in Pipeline, 2016
  • Etubics Corporation - Pipeline by Target, 2016
  • Etubics Corporation - Pipeline by Route of Administration, 2016
  • Etubics Corporation - Pipeline by Molecule Type, 2016
Back to Top